Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer recalls 28 lots of contraceptive pill in US

This article was originally published in Scrip

Executive Summary

Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) Tablets and 14 lots of the generic version of the same drug in the US, following an investigation which revealed that some blister packs may contain an inexact count of inert or active ingredients and that tablets may be out of sequence. The blister packs are supposed to contain 21 tablets of active ingredient and seven inert ones, and errors in the daily dosing leave women without adequate contraception and at risk of unplanned pregnancy. Patients using the affected products are recommended to notify their physician, return the product to the pharmacy and report any adverse events or side effects.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel